Leishmaniasis is a neglected tropical disease, which includes a spectrum of diseases of varying degrees of severity, resulting from a skin lesion to a progressive fatal visceral infection. The development of new therapies for leishmaniasis is essential due to the limited therapeutic options and the high toxicity of drugs. This project aims to study the in vitro and in experimental model of hamster infected with L. (L.) infantum chagasi, new therapies for visceral leishmaniasis, using three approaches: I) the repositioning of drugs (drug repurposing), by evaluating anti-Leishmania activity in vitro and in vivo of drugs already available in other clinical conditions such as nitazoxanide, among others, II) in vitro screening of new synthetic analogues of naphthoquinones, and new synthetic analogues of thiazilidinones as potential anti-Leishmania, which will be studied in partnership with Kings College London (FAPESP 2011/50577-7), III) encapsulation of drugs in controlled release systems of drugs like nanoliposomos. Nanotechnology in the pharmaceutical area can help in several processes, such as through carriers formulations of drugs, allowing a strong reduction of the adverse effects of drugs through a sustained release and targeted to the target cell. Thus, antiparasitic effectiveness studies in vitro and in vivo will be conducted with the compounds, free or encapsulated in liposomes as well as their pharmacokinetic parameters are determined in an animal model. The project's primary objective to obtain a new candidate drug, free or encapsulated in nanolipossomos, contributing to possible new therapies for visceral leishmaniasis.
News published in Agência FAPESP Newsletter about the scholarship: